On August 4, 2026, two separate lawsuits against Novo Nordisk moved forward while federal adverse event data offered a fuller picture of reported side effects across GLP-1 drugs. Neither lawsuit has resulted in any legal finding, and the adverse event reports do not prove a drug caused a given problem. Still, both threads give patients real information to bring into a conversation with their doctor. Here is what the numbers and the litigation actually show today.
The Antoury case is currently active in court, but the lawsuit itself does not establish that Novo Nordisk's drugs caused the harm the plaintiffs describe. A complaint lays out one side's allegations, and it takes discovery, motions, and often a trial before a court reaches any conclusion about what actually happened. That process typically unfolds over months or years, so patients should not expect a quick resolution. In the meantime, the absence of a ruling means the case has not changed anything about how these medications are prescribed or labeled. Patients who want to understand their own risk are better served by looking at the adverse event data reported below and discussing it with their doctor than by tracking the lawsuit's progress.
Malcolm v. Novo Nordisk raises similar concerns about undisclosed risks, but the court filings that would explain exactly what the plaintiffs allege remain sealed. Without access to those details, it isn't possible to say which side effects the case addresses or how the plaintiffs believe the company fell short of its disclosure obligations. Sealed filings are common in early litigation, and they may become public as the case moves forward. Until then, this case remains a pending claim alongside Antoury rather than a confirmed finding, and patients should treat it the same way: worth watching, but not something to act on yet.
Zepbound recorded 6,772 reports of severe nausea, vomiting, or dehydration over the past year, the highest count among the seven GLP-1 drugs tracked in the FAERS database. This number comes from the FDA's Adverse Event Reporting System, which collects reports voluntarily submitted by patients, doctors, and manufacturers, so it reflects how many reports were filed rather than a confirmed rate of how often the side effect occurs. A higher report count can also reflect how widely a drug is prescribed, since more prescriptions generally lead to more reports. Even so, the size of this number makes it a reasonable topic to raise with your doctor, especially if you are currently taking Zepbound or considering it. Bringing your own experience with nausea or dehydration into that conversation will give your doctor more useful information than the raw count alone.
Ozempic logged 779 reports of NAION, a form of vision loss, over the past year, more than any other GLP-1 drug in the FAERS data reviewed here. As with the nausea reports, this figure reflects the number of reports submitted, not a confirmed link between Ozempic and vision loss, and FAERS data cannot establish that the drug caused any individual case. Still, a report count this size is worth raising directly with your doctor, particularly if you have noticed any changes in your vision while taking Ozempic. Your doctor can weigh this alongside your full medical history in a way that a database total cannot.
Mounjaro had 3,643 reports of severe nausea, vomiting, or dehydration over the past year, placing it behind Zepbound but well ahead of several other GLP-1 drugs in the same category. Comparing these totals across drugs can be useful, but it also has limits, since drugs with more prescriptions written will tend to generate more reports regardless of how safe they are relative to one another. If you are taking Mounjaro and have experienced ongoing nausea or signs of dehydration, that combination of symptoms is worth describing to your doctor in detail rather than assuming it is a known and expected side effect. Your doctor can help determine whether your symptoms need attention beyond what you might manage on your own.
None of the numbers or lawsuits described here amount to medical advice, and none of them should lead you to stop or change a GLP-1 medication on your own. What they do offer is a starting point for a more specific conversation with your doctor, whether that means asking about your own risk of severe nausea, mentioning any vision changes you've noticed, or simply asking how your prescriber weighs FAERS data when monitoring patients on these drugs. The two lawsuits against Novo Nordisk are worth watching as they develop, particularly if the sealed details in the Malcolm case become public, but they have not changed what is known or approved today. The most useful step available to you right now is to bring this information into your next appointment rather than waiting for a court to reach a conclusion.
Key details
Antoury v. Novo Nordisk claims are unproven, so no side effect finding exists yet.
Malcolm v. Novo Nordisk also alleges hidden risks, but details stay sealed.
Zepbound had the highest severe nausea report count, 6,772, among tracked drugs.
Ozempic logged 779 vision loss reports, a signal worth discussing with your doctor.
Mounjaro had 3,643 severe nausea and dehydration reports over the past year.